Literature DB >> 31646065

CD4+ Th1 to the rescue in HER-2+ breast cancer.

Lea Lowenfeld1, Shuwen Xu1, Brian J Czerniecki1,2.   

Abstract

HER2 overexpression leads to downregulation of MHC class-I. CD4+ Th1 cytokines, IFNγ and TNFα, and monoclonal antibodies, trastuzumab and pertuzumab, restore MHC class-I expression, and enable CD8+ recognition and cytolysis. Restoration of the anti-HER2 CD4+ Th1 immune response in combination with HER2 targeted therapy appear to be critical to successful anti-HER2 CD8+ immunotherapy.
© 2018 Taylor & Francis Group, LLC.

Entities:  

Keywords:  CD4+ T-cells; CD8+ T-cells; HER2; IFNγ; MHC class-I; TNFα; monoclonal antibodies; pertuzumab; trastuzumab

Year:  2018        PMID： 31646065      PMCID： PMC6791441          DOI： 10.1080/2162402X.2015.1078062

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Authors:  Jashodeep Datta; Cinthia Rosemblit; Erik Berk; Lori Showalter; Prachi Namjoshi; Rosemarie Mick; Kathreen P Lee; Andrew M Brod; Rachel L Yang; Rachel R Kelz; Elizabeth Fitzpatrick; Clifford Hoyt; Michael D Feldman; Paul J Zhang; Shuwen Xu; Gary K Koski; Brian J Czerniecki
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

2.  Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Authors:  Elizabeth A Mittendorf; Guy T Clifton; Jarrod P Holmes; Kevin S Clive; Ritesh Patil; Linda C Benavides; Jeremy D Gates; Alan K Sears; Alexander Stojadinovic; Sathibalan Ponniah; George E Peoples
Journal:  Cancer       Date:  2011-10-11       Impact factor: 6.860

3.  CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Authors:  Jashodeep Datta; Shuwen Xu; Cinthia Rosemblit; Jenessa B Smith; Jessica A Cintolo; Daniel J Powell; Brian J Czerniecki
Journal:  Cancer Immunol Res       Date:  2015-03-19       Impact factor: 11.151

4.  T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Authors:  Kousaku Mimura; Takashi Ando; Isabel Poschke; Dimitrios Mougiakakos; C Christian Johansson; Jiro Ichikawa; Riki Okita; Michael I Nishimura; Diana Handke; Nancy Krug; Aniruddha Choudhury; Barbara Seliger; Rolf Kiessling
Journal:  Int J Cancer       Date:  2010-10-13       Impact factor: 7.396

5.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Authors:  Edith A Perez; E Aubrey Thompson; Karla V Ballman; S Keith Anderson; Yan W Asmann; Krishna R Kalari; Jeanette E Eckel-Passow; Amylou C Dueck; Kathleen S Tenner; Jin Jen; Jian-Bing Fan; Xochiquetzal J Geiger; Ann E McCullough; Beiyun Chen; Robert B Jenkins; George W Sledge; Eric P Winer; Julie R Gralow; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice.

Authors:  P L Lollini; G Nicoletti; L Landuzzi; C De Giovanni; I Rossi; E Di Carlo; P Musiani; W J Muller; P Nanni
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

7.  Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

Authors:  T Z Zaks; S A Rosenberg
Journal:  Cancer Res       Date:  1998-11-01       Impact factor: 12.701

8.  High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.

Authors:  Gabriela Alexe; Gul S Dalgin; Daniel Scanfeld; Pablo Tamayo; Jill P Mesirov; Charles DeLisi; Lyndsay Harris; Nicola Barnard; Maritza Martel; Arnold J Levine; Shridar Ganesan; Gyan Bhanot
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Authors:  Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki
Journal:  Breast Cancer Res       Date:  2015-05-23       Impact factor: 6.466

10.  PD-L1 expression is increased in a subset of basal type breast cancer cells.

Authors:  Hatem Soliman; Farah Khalil; Scott Antonia
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240
  10 in total
  1 in total

1.  PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXRα/NF-κBp65 Pathway.

Authors:  Xiao Han; Linlin Wei; Bin Wu
Journal:  Onco Targets Ther       Date:  2020-04-21       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.